Remicade

Views & Analysis
3-key-trends-shaping-the-immunology-market

3 key trends shaping the immunology market

From an increase in sales of interleukin inhibitors to the prevalence of biosimilars, this decade has been an eventful one in the immunology industry.

News
JnJ-HiRez-World-Headquarters

No US Remicade biosimilar until at least October

Pulling in sales of $1.78 billion per quarter, Johnson & Johnson’s inflammatory diseases drug Remicade (infliximab) is still the jewel in the crown of the company’s pharma business.